India, Nov. 10 -- Achieve Life Sciences, now doing business as AchieveRx, The Quit Company (QUIT), reported third-quarter 2026 financial results and provided business updates, highlighting progress toward the potential U.S. launch of cytisinicline, its investigational treatment for nicotine dependence. ACHV is trading under the new ticker symbol QUIT effective November 10, 2026.
Third Quarter 2026 Financial Results
For the third quarter of 2026, research and development expenses increased to $6.2 million from $5.3 million a year earlier, while general and administrative expenses rose to $14.3 million from $9.4 million.
Total operating expenses increased to $20.5 million from $14.7 million.
Net loss narrowed to $12.1 million, or $0.11 pe...